实时荧光定量PCR检测人肿瘤细胞NKG2D配体基因表达

目的：建立人肿瘤细胞NKG2D配体基因（MICA、MICB、ULBP1、ULBP2、ULBP3）表达的实时荧光定量PCR（real-time fluorescence quantitativePCR）检测方法。方法：根据NCBI基因库中NKG2D配体基因序列,设计合成引物。用Trizo1法从培养的肿瘤细胞（BEC-7402、HeLa、MDA-MB-435、XWLC-05）中提取总RNA,逆转录成eDNA,建立实时荧光定量PCR检测NKG2D配体基因表达的方法,并检测NKG2D配体在肿瘤细胞株中的表达。结果：经过琼脂糖凝胶电泳、熔解曲线和标准曲线分析,用所设计的引物和SYBR GreenI能够特异扩增和定量检测NKG2D配体基因的表达。该方法成功检测4种肿瘤细胞NKG2D配体基因的表达。结论：建立了人NKG2D配体基因表达的实时荧光定量PCR检测方法,为进一步研究人NKG2D配体在肿瘤免疫中的作用提供了有效手段。     

实时荧光定量PCR 检测人肿瘤细胞NKG2D 配体基因表达

目的:建立人肿瘤细胞NKG2D配体基因(MICA、MICB、ULBP1、ULBP2、ULBP3)表达的实时荧光定量PCR(real-timefluorescence quantitative PCR)检测方法。方法:根据NCBI基因库中NKG2D配体基因序列,设计合成引物。用Trizol法从培养的肿瘤细胞(BEC-7402、HeLa、MDA-MB-435、XWLC-05)中提取总RNA,逆转录成cDNA,建立实时荧光定量PCR检测NKG2D配体基因表达的方法,并检测NKG2D配体在肿瘤细胞株中的表达。结果:经过琼脂糖凝胶电泳、熔解曲线和标准曲线分析,用所设计的引物和SYBR Green I能够特异扩增和定量检测NKG2D配体基因的表达。该方法成功检测4种肿瘤细胞NKG2D配体基因的表达。结论:建立了人NKG2D配体基因表达的实时荧光定量PCR检测方法,为进一步研究人NKG2D配体在肿瘤免疫中的作用提供了有效手段。     

NKG2D及其配体研究进展

NKG2D在NK细胞以及T细胞参与的免疫过程中占有重要的地位。本文介绍了NKG2D受体复合体的组成、结构、功能及表达调控;同时介绍了NKG2D配体的分类,病原体感染对其表达的诱导作用以及异常NKG2D配体的表型及功能,最后简要分析了NKG2D免疫途径在肿瘤免疫和治疗方面的应用前景。     

NKG2D免疫受体及其配体的作用

受到感染或损伤的细胞通过中间受体将信号传导至机体的免疫系统,NKG2D即是这样一种典型的具有较高免疫原性的免疫受体,它的主要作用是传导受损伤细胞产生的信号,诱导机体产生免疫应答。该文总结了近期关于NKG2D和其配体的多样性,以及NKG2D和其配体在信号传导,刺激免疫细胞产生,肿瘤细胞的监督和疾病预防方面的新发现。     

MICA 脱落与肿瘤免疫逃逸：肿瘤免疫治疗新靶标和新策略

MHC Ⅰ类链相关分子（MICA）是自然杀伤细胞和T 细胞上NKG2D 受体的主要活化性配体,在上皮源性肿瘤细胞表面过表达。NKG2D 与MICA 的结合可有效刺激效应细胞对肿瘤细胞的细胞毒作用。然而,临床观察表明,MICA 会在肿瘤的增殖过程中脱落而形成可溶性MICA（sMICA）,这被认为是肿瘤细胞逃脱NKG2D 介导的免疫监视的重要原因。综述在肿瘤细胞中MICA 和NKG2D 的表达与功能、sMICA 的形成与肿瘤免疫逃逸的关联以及介导MICA 脱落的机制,由此探讨肿瘤免疫治疗的新靶点和新策略。     

MICA 基因与肿瘤免疫关系的研究进展

MICA是主要组织相容性复合体I类分子链相关基因(MHC class I chain-related Gene,MIC)家族的功能性基因之一,具有较高的多态性。MICA蛋白在多数正常组织中并不表达,只在正常的胃肠道上皮和大多数上皮性肿瘤细胞表达。MICA可与C型凝集素样活化性受体NKG2D结合,从而影响多种免疫效应细胞的功能,在肿瘤免疫中发挥着重要作用。本文就MICA基因与肿瘤免疫关系的研究进展进行综述。     

生物肽SP对NK细胞NKG2D/NKG2A受体表达的影响

选择NK92-MI细胞为研究体系,研究SP对NK细胞的杀伤活性及功能性受体NKG2D/NKG2A表达的影响,以探讨SP对NK细胞功能的调节作用机制。采用MTT法测定NK92-MI细胞对K562细胞的杀伤活性;采用Real-Time PCR和流式细胞术检测NK92-MI细胞活化性受体NKG2D和抑制性受体NKG2A的基因表达和膜表达。10-14～10-8 mol/L的SP在体外可明显增强NK92-MI细胞的杀伤活性。该浓度范围的SP均可上调NKG2D/NKG2A的mRNA水平;10-14～10-8 mol/L的SP均上调NKG2D/NKG2A的膜表达,较低浓度（10-14 mol/L）的SP仅使NKG2D表达上调,而NKG2A表达无明显变化;SP刺激NKG2D膜表达增加的程度高于NKG2A。生物肽SP调节NK细胞功能性受体NKG2D/NKG2A的表达,可能是SP增强NK细胞杀伤活性的一种原因。     

肿瘤逃逸新机制

基因毒性或细胞应激可诱导自然杀伤细胞活化性受体的表达，即NKG2D受体，从而激活自然杀伤细胞，并向效应T细胞提供共刺激活化信号，继而促进机体免疫系统对抗应激，对机体发挥保护作用。肿瘤发生时，肿瘤相关配体同样激活这条通路，利于机体对肿瘤细胞的清除。然而，人类进展期肿瘤细胞通过水解释放可溶性Ⅰ类主要组织相关性复合体相关的配体MICA，阻断上述通路，从而逃脱这种抗肿瘤机制。     

双歧杆菌脂磷壁酸对B16荷瘤小鼠NK细胞受体NKG2D及其配体的影响

目的探讨双歧杆菌脂磷壁酸（LTA）对黑色素瘤B16荷瘤小鼠NK细胞受体NKG2D及其配体的影响。方法将黑色素瘤B16细胞接种于C57BL／6小鼠皮下,待触及肿块后于荷瘤小鼠皮下注射双歧杆菌LTA。采用MTT、流式细胞术（FCM）、RT-PCR方法分别检测经双歧杆菌LTA处理后B16荷瘤小鼠NK细胞杀伤活性、NK细胞NKG2D受体蛋白表达以及肿瘤组织内Rae-1、H60 mRNA表达的变化。结果与对照组相比,经双歧杆菌LTA处理后,B16荷瘤小鼠的NK细胞杀伤活性增强（P〈0．05）,NK细胞受体NKG2D表达明显增加（P〈0．05）,肿瘤组织Rae-1、H60 mRNA表达上升（P〈0．05）,并具有浓度依赖性。结论双歧杆菌LTA能够增强B16荷瘤小鼠NK细胞的杀伤活性,其机制可能与上调NK细胞受体NKG2D的蛋白表达和肿瘤组织Rae-1、H60 mRNA的表达有关。     

5-氟尿嘧啶增强HeLa细胞对自然杀伤细胞敏感性研究

目的用5-氟尿嘧啶（5-fluorouracil,5-FU）处理HeLa细胞,检测其NKG2D配体MICA的表达及其对NK92细胞杀伤敏感性的变化。方法不同浓度的5-Fu处理HeLa细胞,在不同时间点用半定量PCR及流式细胞术检测HeLa细胞表面的NKG2D配体MICA在RNA及蛋白水平的表达变化情况,用MTT法检测NKG2D抗体封闭NK92细胞的NKG2D受体前后,NK92细胞对HeLa细胞的杀伤作用。结果不同浓度的5．Fu作用于HeLa细胞后,半定量RT—PCR结果显示MICA表达随5-Fu作用浓度增加逐渐增高。而且40μg／ml5．Fu作用于HeLa细胞后随着作用时间的延长（0、8、16、24h）MICA表达增加,流式细胞术检测结果表明,MICA表达的增加主要依赖于未凋亡细胞的MICA表达。在40μg／ml5-FU作用24h,效靶比为2．5：1,5：1,10：1,20：1时都检测到NK92细胞对HeLa细胞的杀伤增强,杀伤作用可部分被NKG2D抗体抑制。结论5-FU能够上调HeLa细胞表面NKG2D配体MICA的表达,增强HeLa细胞对NK92细胞的敏感性,提示化疗联合NK细胞免疫治疗宫颈癌可产生协同作用,提高治疗效果。     

The NKG2D receptor: sensing stressed cells

The activating killer cell lectin-like receptor NKG2D plays a key role in the natural killer (NK) cell-mediated lysis of tumours and infected cells. Unlike other receptors, the ligands recognised by NKG2D are 'induced-self' ligands on stressed cells. This system requires precise regulation because inappropriate expression of NKG2D ligands might compromise NK cell activation. For therapeutic purposes it is essential to understand the mechanisms that regulate the expression and function of the NKG2D system. This review focuses on the importance of the signalling pathways involved in the regulation of the NKG2D receptor and its ligand expression in arming the immune response against infected or tumour cells and for the identification of new molecular targets and therapeutic strategies.     

The NKG2D receptor and its ligands-recognition beyond the "missing self"?

NKG2D is a surface receptor that activates natural killer (NK) cells and delivers a co-stimulatory signal to CD8-positive T cells. The ligands of NKG2D are induced by cellular stress and are specifically expressed by some tumor cells. This sparked the idea of an alternative regulation of NK cells by expression of "induced self" ligands on target cells which can overcome the inhibition imparted by MHC class I-specific inhibitory receptors.     

Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked

Background

There is limited understanding of the dysregulation of the innate immune system in multiple myeloma (MM). We analysed the expression of the activating receptor NKG2D on NK cells and T cells of MM patients and investigated the impact of soluble versus membrane-bound NKG2D ligands on the expression of NKG2D.

Design

NKG2D expression on NK cells and CD8+ αβ T cells from patients with MM or monoclonal gammopathy of uncertain significance and healthy controls was examined flow-cytometrically. Sera from patients and controls were analysed for soluble NKG2D ligands (sNKG2D ligands).

Results

Significantly fewer NK cells and CD8+ αβ T cells from patients expressed NKG2D compared to healthy controls (NK cells: median 54% interquartile range (IQR) 32–68 versus 71% IQR 44–82%, P = 0.017, CD8+ αβ T cells: median 63% IQR 52–81 versus 77% IQR 71–90%, P = 0.018). The sNKG2D ligand sMICA was increased in patients [median 175 (IQR 87–295) pg/ml] versus controls [median 80 (IQR 32–129) pg/ml, P < 0.001], but levels of sMICA did not correlate with NKG2D expression on effector cells. To elucidate the mechanism of NKG2D down-regulation, we incubated lymphocytes from healthy donors in the presence of sNKG2D ligands or in co-culture with MM cell lines. sNKG2D ligands in clinically relevant concentrations did not down-regulate NKG2D expression, but co-culture of effector cells with myeloma cells with high surface expression of NKG2D ligands reduced NKG2D expression significantly.

Conclusions

These results indicate that MM is associated with a significant reduction in NKG2D expression which may be contact-mediated rather than caused by soluble NKG2D ligands.     

NKG2D is a costimulatory receptor for human naive CD8+ T cells

In humans, all alpha beta CD8+ T cells express NKG2D, but in mouse, it is only expressed by activated and memory CD8+ T cells. We purified human naive CD8+ T cells to show that NKG2D serves as a costimulatory receptor for TCR induced Ca2+ mobilization and proliferation. The resulting effector cells are skewed toward a type 1 phenotype and produce high levels of IFN-gamma and TNF-alpha. NKG2D ligands, MHC class I chain-related (MIC)A, MICB, and UL16-binding proteins are expressed on the proliferating cells and NKG2D is down-regulated. The addition of the homeostatic cytokines IL-7 and IL-15 to the culture medium not only enhances proliferation but also counteracts the down-regulation of NKG2D, more so than the addition of IL-2. These results indicate that NKG2D can regulate the priming of human naive CD8+ T cells, which may provide an alternative mechanism for potentiating and channeling the immune response.     

Human tumor-derived exosomes down-modulate NKG2D expression

NKG2D is an activating receptor for NK, NKT, CD8(+), and gammadelta(+) T cells, whose aberrant loss in cancer is a key mechanism of immune evasion. Soluble NKG2D ligands and growth factors, such as TGFbeta1 emanating from tumors, are mechanisms for down-regulating NKG2D expression. Cancers thereby impair the capacity of lymphocytes to recognize and destroy them. In this study, we show that exosomes derived from cancer cells express ligands for NKG2D and express TGFbeta1, and we investigate the impact of such exosomes on CD8(+) T and NK cell NKG2D expression and on NKG2D-dependent functions. Exosomes produced by various cancer cell lines in vitro, or isolated from pleural effusions of mesothelioma patients triggered down-regulation of surface NKG2D expression by NK cells and CD8(+) T cells. This decrease was rapid, sustained, and resulted from direct interactions between exosomes and NK cells or CD8(+) T cells. Other markers (CD4, CD8, CD56, CD16, CD94, or CD69) remained unchanged, indicating the selectivity and nonactivatory nature of the response. Exosomal NKG2D ligands were partially responsible for this effect, as down-modulation of NKG2D was slightly attenuated in the presence of MICA-specific Ab. In contrast, TGFbeta1-neutralizing Ab strongly abrogated NKG2D down-modulation, suggesting exosomally expressed TGFbeta as the principal mechanism. Lymphocyte effector function was impaired by pretreatment with tumor exosomes, as these cells exhibited poor NKG2D-dependent production of IFN-gamma and poor NKG2D-dependent killing function. This hyporesponsiveness was evident even in the presence of IL-15, a strong inducer of NKG2D. Our data show that NKG2D is a likely physiological target for exosome-mediated immune evasion in cancer.     

TNK cells (NKG2D<Superscript>+</Superscript> CD8<Superscript>+</Superscript> or CD4<Superscript>+</Superscript> T lymphocytes) in the control of human tumors

Innate and adaptive immune responses have many interactions that are regulated by the balance of signals initiated by a variety of activatory and inhibitory receptors. Among these, the NKG2D molecule was identified as expressed by T lymphocytes, including most CD8⁺ cells and a minority of CD4⁺ cells, designated TNK cells in this paper. Tumor cells may overexpress the stress-inducible NKG2D ligands (NKG2DLs: MICA/B, ULBPs) and the NKG2D signaling has been shown to be involved in lymphocyte-mediated anti-tumor activity. Aberrant expression of NKG2DLs by cancer cells, such as the release of soluble form of NKG2DLs, can lead to the impairment of these immune responses. Here, we discuss the significance of NKG2D in TNK-mediated anti-tumor activity. Our studies demonstrate that NKG2D⁺ T cells (TNK) are commonly recruited at the tumor site in melanoma patients where they may exert anti-tumor activity by engaging both TCR and NKG2D. Moreover, NKG2D and TCR triggering was also observed by peripheral blood derived T lymphocyte- or T cell clone-mediated tumor recognition, both in melanoma and colorectal cancer (CRC) patients. Notably, heterogeneous expression of NKG2DLs was found in melanoma and CRC cells, with a decrease of these molecules along with tumor progression. Therefore, through the mechanisms that govern NKG2D engagement in anti-tumor activity and the expression of NKG2DLs by tumor cells that still need to be dissected, we showed that NKG2D expressing TNK cells are a relevant T cell subtype for immunosurveillance of tumors and we propose that new immunotherapeutic interventions for cancer patients should be aimed also at enhancing NKG2DLs expression by tumor cells. This paper is a focused research review based on a presentation given at the sixth annual meeting of the Association for Immunotherapy of Cancer (CIMT), held in Mainz, Germany, 15–16 May 2008.     

Tumor-targeted delivery of IL-2 by NKG2D leads to accumulation of antigen-specific CD8+ T cells in the tumor loci and enhanced anti-tumor effects

Interleukin-2 (IL-2) has been shown to promote tumor-specific T-cell proliferation and differentiation but systemic administration of IL-2 results in significant toxicity. Therefore, a strategy that can specifically deliver IL-2 to the tumor location may alleviate concerns of toxicity. Because NKG2D ligands have been shown to be highly expressed in many cancer cells but not in healthy cells, we reason that a chimeric protein consisting of NKG2D linked to IL-2 will lead to the specific targeting of IL-2 to the tumor location. Therefore, we created chimeric proteins consisting of NKG2D linked to Gaussia luciferase (GLuc; a marker protein) or IL-2 to form NKG2D-Fc-GLuc and NKG2D-Fc-IL2, respectively. We demonstrated that NKG2D linked to GLuc was able to deliver GLuc to the tumor location in vivo. Furthermore, we showed that TC-1 tumor-bearing mice intramuscularly injected with DNA encoding NKG2D-Fc-IL2, followed by electroporation, exhibited an increased number of luciferase-expressing E7-specific CD8+ T cells at the tumor location. More importantly, treatment with the DNA construct encoding NKG2D-Fc-IL2 significantly enhanced the therapeutic anti-tumor effects generated by intradermal vaccination with therapeutic HPV DNA in tumor-bearing mice. Therefore, by linking NKG2D to IL2, we are able to specifically deliver IL-2 to the tumor location, enhancing antigen-specific T-cell immune response and controlling tumor growth. Our approach represents a platform technology to specifically deliver proteins of interest to tumor loci.